Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors

European Journal of Endocrinology

Volumn 141, Issue 1, 1999, Pages 1-14

  Schally, Andrew V ^a   Nagy, Attila ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 PYRROLINODOXORUBICIN; AN 162; AN 215; BOMBESIN; BOMBESIN ANTAGONIST; BOMBESIN DERIVATIVE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOXORUBICIN DERIVATIVE; GONADORELIN; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

BINDING AFFINITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER MODEL; COLORECTAL CANCER; CONJUGATE; DRUG CYTOTOXICITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; LUNG SMALL CELL CANCER; NONHUMAN; NUDE MOUSE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RAT; REVIEW; STOMACH CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BOMBESIN; FEMALE; GASTRIN-RELEASING PEPTIDE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASMS; RECEPTORS, CELL SURFACE; RECEPTORS, LHRH; SOMATOSTATIN;

EID: 0032797051     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1410001     Document Type: Review

References (102)

1. Chabner B. Cancer Chemotherapy. Principles and Practice. Philadelphia: J B Lippincott, 1990.
2. Frei E III & Antman KH. Combination chemotherapy, dose, and schedule. In Cancer Medicine, edn 4, pp 817-837. Eds JR Holland, E Frei III. RR Bast Jr. DE Kufe, DL Morton & RR Weichselbaum. Baltimore: Williams and Wilkins, 1997.
3. Magrath T. Targeted approaches to cancer therapy. International Journal of Cancer 1994 56 163-166.
4. Ehrlich P. The relationship existing between chemical constitution, distribution, and pharmacological action. In The Collected Papers of Paul Ehrlich, vol. 1, pp 596-618. Eds F Himmelweite. M Marquardt & H Dale. Elmsford, New York: Pergamon, 1956.
5. Kohler G & Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975 256 495-497.
6. Baldwin RW. Monoclonal antibody targeting of anticancer agents: Mühlbock Memorial Lecture. European Journal of Cancer and Clinical Oncology 1985 21 1281-1285.
7. Hertler AA & Frankel AE. Immunotoxins: A clinical review of their use in the treatment of malignancies. Journal of Clinical Oncology 1989 7 1932-1942.
8. Pastan I & FitzGerald D. Recombinant toxins for cancer treatment. Science 1991 254 1173-1177.
9. FitzGerald D & Pastan I. Targeted toxin therapy for the treatment of cancer. Journal of the National Cancer Institute 1989 81 1455-1463.
10. Singh V, Sairam MR, Bhargavi GN & Akhras RG. Hormonotoxins. Preparation and characterization of ovine luteinizing hormone-gelonin conjugate. Journal of Biological Chemistry 1989 264 3089-3095.
11. Yen M-Y, Roffler SR & Yu M-H. Doxorubicin: Monoclonal antibody conjugate for therapy of human cervical carcinoma. International Journal of Cancer 1992 51 274-282.
12. Schally AV, Nagy A, Szepeshazi K, Pinski J, Halmos G, Armatis P et al. LH-RH analogs with cytotoxic radicals. In Treatment with Gn-RH Analogs: Controversies and Perspectives, pp 33-44. Eds M Filicori & C Flamigni. Carnforth, UK: Parthenon Publishing, 1996.
13. Konyves I. Estramustine phosphate (Estracyt) in the treatment of prostate carcinoma. International Urology and Nephrology 1989 21 393-397.
14. Konyves I, Muntzing J & Rozencweig M. Chemotherapy principles in the treatment of prostatic cancer. Prostate 1984 5 55-62.
15. Freer RJ & Stewart JM. Alkylating analogs of peptide hormones. 1. Synthesis and properties of p-[N,N-Bis(2-chloroethyl)amino]-phenylbutyryl derivatives of bradykinin and bradykinin potentiating factor. Journal of Medicinal Chemistry 1972 15 1-5.
16. Channabasavaiah K & Stewart JM. New analogs of luliberin which inhibit ovulation in the rat. Biochemical and Biophysical Research Communications 1979 86 1266-1273.
17. Paiva TB, Paiva ACM, Freer RJ & Stewart JM. Alkylating analogs of peptide hormones. 2. Synthesis and properties of p-[N,N-Bis(2-chloroethyl)amino]phenylbutyryl derivatives of angiotensin II. Journal of Medicinal Chemistry 1972 15 6-8.
18. Varga JM. Hormone-drug conjugates. Methods in Enzymology 1985 112 259-269.
19. Bajusz S, Janáky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G et al. Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6. Proceedings of the National Academy of Sciences of the USA 1989 86 6318-6322.
20. Bajusz S, Janáky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G et al. Highly potent metallopeptide analogues of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the USA 1989 86 6313-6317.
21. Janáky T, Juhász A, Bajusz S, Csernus V, Srkalovic G Bokser L et al. Analogues of luteinizing hormone-releasing hormone containing cytotoxic groups. Proceedings of the National Academy of Sciences of the USA 1992 89 972-976.
22. Radulovic S, Nagy A, Szöke B & Schally AV. Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Letters 1992 62 263-271.
23. Schally AV & Comaru-Schally AM. Hypothalamic and other peptide hormones. In Cancer Medicine, edn 4, pp 1067-1086. Eds JR Holland, E Frei III, RR Bast Jr. DE Kufe DL Morton & RR Weichselbaum. Baltimore: Williams and Wilkins, 1997.
24. Emons G & Schally AV. The use of luteinizing hormone-releasing hormone agonists and antagonists in gynecological cancer. Human Reproduction 1994 9 1364-1369.
25. th World Congress of Endometriosis. October 1996, Yokohama. Japan, pp 401-413. Eds H Minaguchi & O Sugimioto. Carnforth, UK: Parthenon Publishing, 1997.
26. Schally AV & Comaru-Schally AM. Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions. Advanced Drug Delivery Reviews 1997 28 157-169.
27. Emons G, Ortmann O, Schulz K-D & Schally AV Growth-inhibitory actions of analogues of luteinizing hormone-releasing hormone on tumor cells. Trends in Endocrinology and Metabolism 1997 8 355-362.
28. Stojilkovic SS & Catt KJ. Expression and signal transduction pathways of gonadotropin releasing hormone receptors. Recent Progress in Hormone Research 1995 30 161-205.
29. Fekete M, Redding TW, Comaru-Schally AM, Pontes AE, Connelly RW, Srkalovic G et al. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin and epidermal growth factor in rat and human prostate cancers and in benign prostatic hyperplasia. Prostate 1989 14 191-208.
30. Qayum A, Gullick W, Clayton RC, Sikora K & Waxman J. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumor receptors. British Journal of Cancer 1990 62 96-99.
31. Koppán M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM et al. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate 1999 38 151-158.
32. Limonta P, Dondi D, Moretti RM, Maggi R & Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. Journal of Clinical Endocrinology and Metabolism 1992 75 207-212.
33. Lamharzi N, Halmos G, Jungwirth A & Schally AV. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice. International Journal of Oncology 1998 13 429-435.
34. Limonta P, Dondi D, Moretti RM, Fermo D, Garattini E & Motta M. Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. Journal of Clinical Endocrinology and Metabolism 1993 76 797-800.
35. Miller WR, Scott WN, Morris R, Fraser HM & Sharps RM. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 1985 313 231-233.
36. Eidne KA, Flanagan CA, Harris NS & Millar RP. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. Journal of Clinical Endocrinology and Metabolism 1987 64 425-432.
37. Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K et al. Inhibition of growth of MCF-7-MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Research and Treatment 1992 21 35-45.
38. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. Journal of Clinical Laboratory Analysis 1989 3 137-147.
39. 6] luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer. International Journal of Oncology 1998 12 489-498.
40. Irmer G, Bürger C, Müller R, Ortman O, Peter V, Kakar S et al Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Research 1995 55 817-822.
41. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K et al. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone. Journal of the National Cancer Institute 1997 89 1803-1809.
42. 6]-luteinizing hormone-releasing hormone and epidermal growth factor in human endometrial carcinoma. Cancer Research 1990 50 1841-1846.
43. Emons G, Schröder B, Ortmann O, Westphalen S, Schulz K-D & Schally AV. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. Journal of Clinical Endocrinology and Metabolism 1993 77 1458-1464.
44. Kakar SS, Grizzle WE & Neill JD, The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Molecular and Cellular Endocrinology 1994 106 145-149.
45. Halmos G, Nagy A, Lamharzi N & Schally AV Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high-affinity to human breast cancers. Cancer Letters 1999 136 129-136.
46. Karten MJ & Rivier JE. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocrine Reviews 1986 7 44-66.
47. Nagy A, Szöke B & Schally AV. Selective coupling of methotrexate to peptide hormone carriers through a γ-carboxamide linkage of its glutamic acid moiety: Benzotriazol-1-yloxytris(dimethyl-amino)phosphonium hexafluorophosphate activation in salt coupling. Proceedings of the National Academy of Sciences of the USA 1993 90 6373-6376.
48. Hurwitz E, Levy R, Maron R, Wilchek M, Arnon R & Sela M. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Research 1975 35 1175-1181.
49. Casazza AM, Trail PA & Hellstrom KE. Drug immunotargeting for carcinomas: a reality at last? Annals of Oncology 1994 5 705-708.
50. Shen WC & Ryser HJP. cis-Aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkage releasing drug from lysosomotropic conjugate. Biochemical and Biophysical Research Communications 1981 102 1048-1054.
51. Trouet A, Masquelier M, Baurain R & Deprez-de Campeneere D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proceedings of the National Academy of Sciences of the USA 1982 79 626-629.
52. Zunino F, Gambetta R, Vigevani A, Penco S, Geroni C & DiMarco A. Biological activity of daunorubicin linked to proteins via the methylketone side chain. Tumori 1981 67 521-524.
53. Zunino F, Savi G, Giuliani F, Gambetta R, Supino R, Tinelli S et al. Comparison of antitumor effects of daunorubicin covalently linked to poly-L-amino acid carriers. European Journal of Cancer and Clinical Oncology 1984 20 421-425.
54. Nagy A, Schally AV Armatis P, Szepeshazi K, Halmos G, Kovacs M et al Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proceedings of the National Academy of Sciences of the USA 1996 93 7269-7273.
55. Nagy A, Armatis P & Schally AV. High-yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: Structure-activity relationship of daunosamine-moditied derivatives of doxorubicin. Proceedings of the National Academy of Sciences of the USA 1996 93 2464-2469.
56. Pinski J, Schally AV, Yano T, Szepeshazi K, Halmos G Groot K et al. Inhibition of growth of experimental prostate cancer in rats by LH-RH analogs linked to cytotoxic radicals. Prostate 1993 23 165-178.
57. Szepeshazi K, Schally AV, Juhász A, Nagy A & Janáky T. Effects of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on growth of estrogen-independent MXT mouse mammary carcinoma in vivo. Anti-Cancer Drugs 1992 3 109-116.
58. Miyazaki M, Schally AV, Nagy A, Lamharzi N, Halmos G, Szepeshazi K et al. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. American Journal of Obstetrics and Gynecology 1999 (In Press).
59. Szepeshazi K, Schally AV, Nagy A, Halmos G & Groot K. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen-independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis. Anti-Cancer Drugs 1997 8 974-987.
60. Kahán Z, Nagy A, Schally AV, Halmos G, Arencibia JM & Groot K. Complete regression of MX-1 human breast cancer xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone. AN-207. Cancer 1999 (In Press).
61. Jungwirth A, Schally AV, Nagy A, Pinski J, Groot K, Galvan C, et al. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. International Journal of Oncology 1997 10 877-884.
62. Spindel ER, Giladi E, Segerson TP & Nagalla S. Bombesin-like peptides: Of ligands and receptors. Recent Progress in Hormone Research 1995 48 365-391.
63. Cuttitta F, Carney DN, Mulshine JW, Moody TW, Fedorko J, Fischler A et al. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 1985 316 823-826.
64. Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R et al. BRS-3: A novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. Journal of Biological Chemistry 1993 268 5979-5984.
65. 13]bombesin distinct from the receptor for gastrin-releasing peptide: Identification of a fourth bombesin receptor subtype (BB4). Proceedings of the National Academy of Sciences of the USA 1995 92 6205-6209.
66. Halmos G, Wittliff JL & Schally AV. Characterization of bombesin/ gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression. Cancer Research 1995 55 280-287.
67. Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K et al. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonist RC-3095 and LH-RH antagonist SB-75 on growth of MCF-7 Mill human breast cancer xenografts in athymic nude mice. Cancer 1994 73 1229-1238.
68. Schally AV. Hypothalamic hormones from neuroendocrinology to cancer therapy. Anticancer Drugs 1994 5 115-130.
69. Radulovic S, Cai R-Z, Serfozo P, Groot K, Redding TW, Pinski J & Schally AV. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi. International Journal of Peptide and Protein Research 1991 38 593-600.
70. 2 or its derivatives. Proceedings of the National Academy of Sciences of the USA 1994 91 12664-12668.
71. Nagy A, Armatis P, Cai R-Z, Szepeshazi K, Halmos G & Schally AV. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative. 2-pyrrolinodoxorubicin. Proceedings of the National Academy of Sciences of the USA 1997 94 652-656.
72. Kiaris H, Schally AV, Nagy A & Sun B. The cytotoxic bombesin analog AN-215 inhibits the growth of H-69 small cell lung carcinoma in vivo. Proceedings of 3rd World Congress on Advances in Oncology and 1st International Symposium on Molecular Medicine, 15-17 October 1998, Crete, Greece. (Abstract).
73. Lamberts SWJ. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Reviews 1991 12 450-482.
74. Schally AV. Oncological application of somatostatin analogues. Cancer Research 1988 48 6977-6985.
75. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P et al. SMS-201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sciences 1982 31 1133-1140.
76. Cai R-Z. Szöke B, Lu R, Fu D, Redding TW & Schally AV. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proceedings of the National Academy of Sciences of the USA 1986 83 1896-1900.
77. Pollak MN & Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proceedings of the Society for Experimental Biology and Medicine 1998 217 143-152.
78. Hofland LJ, Van Koetsveld PM, Waaijers M, Zuyderwijk J & Lamberts SWJ. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology 1994 134 301-306.
79. Reubi JC, Krenning EP, Lamberts SWJ & Kvols L. In vitro detection of somatostatin receptors in human tumors. Metabolism 1992 41 (Suppl 2) 104-110.
80. Srkalovic G, Cai R-Z & Schally AV. Evaluation of receptors for somatostatin in various tumors using different analogs. Journal of Clinical Endocrinology and Metabolism 1990 70 661-669.
81. Weckbecker C, Raulf F, Stolz B & Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacology and Therapeutics 1993 60 245-264.
82. Reubi JC, Waser B, Foekens JA, Klijn JGM, Lamberts SWJ & Laissue J. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relation to EGF receptors. International Journal of Cancer 1990 46 416-420.
83. Reubi JC, Laissue J, Krenning E & Lamberts SW. Somatostatin receptors in human cancer: Incidence, characteristics, functional correlates and clinical implications. Journal of Steroid Biochemistry and Molecular Biology 1992 43 27-35.
84. Bell GI & Reisine T. Molecular biology of somatostatin receptors. Trends in Neuroscience 1993 16 34-38.
85. Patel YC, Greenwood MT, Panetta R, Hukovic N, Grigorakis S, Robertson LA et al. Molecular biology of somatostatin receptor subtypes. Metabolism 1996 45 (Suppl 1) 31-38.
86. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H & Srikant CB. The somatostatin receptor family, life Sciences 1995 57 1249-1265.
87. Schonbrunn A, Gu YZ, Dournard P, Beaudet A, Tannenbaum GS & Brown PJ. Somatostatin receptor subtypes: Specific expression and signaling properties. Metabolism 1996 45 (Suppl 1) 8-11.
88. Reisine T & Bell GI. Molecular biology of somatostatin receptors. Endocrine Reviews 1995 16 427-442.
89. Buscail L, Delesque N, Estève J-P, Saint-Laurent N, Prats H, ClercP et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proceedings of the National Academy of Sciences of the USA 1994 91 2315-2319.
90. Buscail L, Estève J-P, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll A-M et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by SSTR2 and SSTR5 somatostatin receptor subtypes through different mechanisms. Proceedings of the National Academy of Sciences of the USA 1995 92 1580-1584.
91. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Research 1996 56 1823-1827.
92. 3]octreotide: the Rotterdam experience with more than 1000 patients. European Journal of Nuclear Medicine 1993 20 716-730.
93. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R & Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 1998 351 417-418.
94. Nagy A, Schally AV, Halmos G, Armatis P, Cai R-Z, Csernus V et al. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proceedings of the National Academy of Sciences of the USA 1998 95 1794-1799.
95. Kahán Z, Nagy A, Schally AV. Hébert F, Sun B, Groot K et al. Inhibition of growth of MX-1. MCF-7 MIII and MDA-MB-231 human breast cancers after administration of targeted cytotoxic analog of somatostatin, AN-238. International journal of Cancer 1999 (In Press).
96. Evans AA, Crook T, Laws SAM, Gough AC, Royle GT & Primrose JN. Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. British Journal of Cancer 1997 75 798-803.
97. Koppán M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G et al. Targeted cytotoxic analogue of somatostatin AN-238 inhibits the growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Research 1998 58 4132-4137.
98. Plonowski A, Schally AV, Nagy A, Sun B & Szepeshazi K. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analog AN-238. Cancer Research 1999 59 1947-1953.
99. Szöke B, Horvath J, Halmos G, Rekasi Z, Groot K, Nagy A et al. LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro. Peptides 1994 15 359-366.
100. Tritton TR & Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 1982 217 248-250.
101. Tritton TR. Cell surface actions of adriamycin. Pharmacology and Therapeutics 1991 49 293-309.
102. Kovács M, Schally AV, Nagy A, Koppán M & Groot K. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proceedings of the National Academy of Sciences of the USA 1997 94 1420-1425.